Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 29;31(4):1774-1802.
doi: 10.3390/curroncol31040135.

The Canadian Breast Cancer Symposium 2023 Meeting Report

Tulin Cil  1 , Jean-François Boileau  2 , Stephen Chia  3 , M J DeCoteau  4 , Katarzyna J Jerzak  5 , Anne Koch  1 , Nancy Nixon  6 , May Lynn Quan  6 , Amanda Roberts  5 , Christine Brezden-Masley  7
Affiliations

The Canadian Breast Cancer Symposium 2023 Meeting Report

Tulin Cil et al. Curr Oncol. .

Abstract

On 15-16 June 2023, healthcare professionals and breast cancer patients and advocates from across Canada met in Toronto, Ontario, for the 2023 Canadian Breast Cancer Symposium (CBSC.). The CBSC. is a national, multidisciplinary event that occurs every 2 years with the goal of developing a personalized approach to the management of breast cancer in Canada. Experts provided state-of-the-art information to help optimally manage breast cancer patients, including etiology, prevention, diagnosis, experimental biology, and therapy of breast cancer and premalignant breast disease. The symposium also had the objectives of increasing communication and collaboration among breast cancer healthcare providers nationwide and providing a comprehensive and real-life review of the many facets of breast cancer. The sessions covered the patient voice, the top breast cancer papers from different disciplines in 2022, artificial intelligence in breast cancer, systemic therapy updates, the management of central nervous system metastases, multidisciplinary management of ductal carcinoma in situ, special populations, optimization-based individual prognostic factors, toxicity management of novel therapeutics, survivorship, and updates in surgical oncology. The key takeaways of these sessions have been summarized in this conference report.

Keywords: CNS metastases; breast cancer; new advances; patient voice; surgical oncology; systemic therapy.

PubMed Disclaimer

Conflict of interest statement

T.C. has received grant funding from the Canadian Institute of Health Research and Academic Funding Plan at University Health Network. J.-F.B. has received funding for advisory boards/consultancy and speaker honoraria from AstraZeneca, Merck, Novartis, Lilly, Roche, Pfizer, and Exact Sciences. S.C. reports honoraria from Novartis, Hoffmann LaRoche, Pfizer, Eli Lilly, Merck, AstraZeneca, Exact Sciences, and Gilead. M.D. and/or her organization, Rethink, has received education grants, sponsorship, and funding for advisory boards/consultancy and speaker honoraria from Astra Zeneca, Daichi Sankyo, Gilead, Lilly, Merck, Novartis, Pfizer, Roche, Seagen, and Gilead. K.J.J. has acted as consultant/speaker/advisory board member for Amgen, AstraZeneca, Apo Biologix, Daiichi Sankyo, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc, Pfizer, Roche, Seagen, Novartis, and Viatris, and has received grants from AstraZeneca, Eli Lilly, and Seagen. A.K. has no conflicts of interest to declare. N.N. has acted as speaker/ad board member for Astra Zeneca, Novartis, Seagen, Merck, Pfizer, Gilead, Knight therapeutics, and exact sciences, and has received grants from Pfizer, Astra Zeneca, Seagen, Merck, Novartis, and Gilead. M.L.Q. has received honoraria from Western Canada Pharma Alliance and Sentimag, and grant funding from the Canadian Institute of Health Research and the Canadian Cancer Society. A.R. has received grants from the Canadian Cancer Society and the Association of Fundraising Professionals Innovation. C.B.-M. has received funding for advisory boards/consultancy and speaker honoraria from Astra Zeneca, Agendia, Bristol-Myers Squibb, Knight, Merck, Lilly, Novartis, Pfizer, Roche, Seagen, Taiho, Sanofi, Mylan, and Gilead.

Similar articles

See all similar articles

References

    1. Partridge A.H., Niman S.M., Ruggeri M., Peccatori F.A., Azim H.A., Colleoni M., Saura C., Shimizu C., Sætersdal A.B., Kroep J.R., et al. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. N. Engl. J. Med. 2023;388:1645–1656. doi: 10.1056/NEJMoa2212856. - DOI - PMC - PubMed
    1. Johnston S.R.D., Toi M., O’Shaughnessy J., Rastogi P., Campone M., Neven P., Huang C.-S., Huober J., Jaliffe G.G., Cicin I., et al. Abemaciclib plus Endocrine Therapy for Hormone Receptor-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer (monarchE): Results from a Preplanned Interim Analysis of a Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2023;24:77–90. doi: 10.1016/S1470-2045(22)00694-5. - DOI - PMC - PubMed
    1. Cortes J., Rugo H.S., Cescon D.W., Im S.-A., Yusof M.M., Gallardo C., Lipatov O., Barrios C.H., Perez-Garcia J., Iwata H., et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N. Engl. J. Med. 2022;387:217–226. doi: 10.1056/NEJMoa2202809. - DOI - PubMed
    1. Seung S.J., Traore A.N., Pourmirza B., Fathers K.E., Coombes M., Jerzak K.J. A Population-Based Analysis of Breast Cancer Incidence and Survival by Subtype in Ontario Women. Curr. Oncol. 2020;27:e191–e198. doi: 10.3747/co.27.5769. - DOI - PMC - PubMed
    1. Rugo H.S., Bardia A., Marmé F., Cortes J., Schmid P., Loirat D., Trédan O., Ciruelos E., Dalenc F., Pardo P.G., et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J. Clin. Oncol. 2022;40:3365–3376. doi: 10.1200/JCO.22.01002. - DOI - PubMed

Publication types

Grants and funding